Identification of Unique Sensitizing Targets for Anti-inflammatory CDDO-Me in Metastatic Melanoma by a Large-scale Synthetic Lethal RNAi Screening

Overview

Journal Pigment Cell Melanoma Res

Date 2012 Oct 2

PMID 23020131

Citations 16

Authors

Yong Qin

Wuguo Deng

Suhendan Ekmekcioglu

Elizabeth A Grimm

Affiliations

Soon will be listed here.

Abstract

CDDO-Me has been shown to exert potent anti-inflammatory activity for chronic kidney disease and antitumor activity for several tumors, including melanoma, in early clinical trials. To improve CDDO-Me response in melanoma, we utilized a large-scale synthetic lethal RNAi screen targeting 6000 human druggable genes to identify targets that would sensitize melanoma cells to CDDO-Me. Based on screening results, five unique genes (GNPAT, SUMO1, SPINT2, FLI1, and SSX1) significantly potentiated the growth inhibitory effects of CDDO-Me and induced apoptosis in A375, a BRAF mutated melanoma line (P < 0.001). These five genes were then individually validated as targets to potentiate CDDO-Me activity, and related downstream signaling pathways of these genes were analyzed. In addition, the levels of phosphorylated Erk1/2, Akt, GSK-2, and PRAS40 were dramatically decreased by downregulating each of these five genes separately, suggesting a set of common mediators. Our findings indicate that GNPAT, SUMO1, SPINT2, FLI1, and SSX1 play critical roles in synergy with inflammation pathways in modulating melanoma cell survival and could serve as sensitizing targets to enhance CDDO-Me efficacy in melanoma growth control.

Citing Articles

CSE triggers ferroptosis via SIRT4-mediated GNPAT deacetylation in the pathogenesis of COPD.

Li C, Chen F, Lin L, Li J, Zheng Y, Chen Q Respir Res. 2023; 24(1):301.

PMID: 38041059 PMC: 10691148. DOI: 10.1186/s12931-023-02613-0.

Peroxisome disruption alters lipid metabolism and potentiates antitumor response with MAPK-targeted therapy in melanoma.

Huang F, Cai F, Dahabieh M, Gunawardena K, Talebi A, Dehairs J J Clin Invest. 2023; 133(20).

PMID: 37616051 PMC: 10575734. DOI: 10.1172/JCI166644.

Orthogonal Optimization, Characterization, and In Vitro Anticancer Activity Evaluation of a Hydrogen Peroxide-Responsive and Oxygen-Reserving Nanoemulsion for Hypoxic Tumor Photodynamic Therapy.

Hong L, Wang J, Zhou Y, Shang G, Guo T, Tang H Cancers (Basel). 2023; 15(5).

PMID: 36900370 PMC: 10000418. DOI: 10.3390/cancers15051576.

Fermitin family member 2 promotes melanoma progression by enhancing the binding of p-α-Pix to Rac1 to activate the MAPK pathway.

Huang S, Deng W, Wang P, Yan Y, Xie C, Cao X Oncogene. 2021; 40(37):5626-5638.

PMID: 34321603 PMC: 8445820. DOI: 10.1038/s41388-021-01954-8.

LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma.

Zhu Y, Li C, Li G, Feng H, Xia T, Wong C Cell Mol Gastroenterol Hepatol. 2020; 10(4):811-828.

PMID: 32615164 PMC: 7505810. DOI: 10.1016/j.jcmgh.2020.06.009.

References

Qin Y, Ekmekcioglu S, Liu P, Duncan L, Lizee G, Poindexter N . Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res. 2011; 9(11):1537-50. PMC: 3387749. DOI: 10.1158/1541-7786.MCR-11-0279. View

Tran K, Risingsong R, Royce D, Williams C, Sporn M, Liby K . The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. Cancer Prev Res (Phila). 2012; 5(5):726-34. DOI: 10.1158/1940-6207.CAPR-11-0404. View

Raslova H, Komura E, Le Couedic J, Larbret F, Debili N, Feunteun J . FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. J Clin Invest. 2004; 114(1):77-84. PMC: 437972. DOI: 10.1172/JCI21197. View

Thimmulappa R, Fuchs R, Malhotra D, Scollick C, Traore K, Bream J . Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. Antioxid Redox Signal. 2007; 9(11):1963-70. PMC: 2396226. DOI: 10.1089/ars.2007.1745. View

Tang C, Grimm E . Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem. 2003; 279(1):288-98. DOI: 10.1074/jbc.M310821200. View

Liu D, Nagan N, Just W, Rodemer C, Thai T, Zoeller R . Role of dihydroxyacetonephosphate acyltransferase in the biosynthesis of plasmalogens and nonether glycerolipids. J Lipid Res. 2005; 46(4):727-35. DOI: 10.1194/jlr.M400364-JLR200. View

Konopleva M, Contractor R, Kurinna S, Chen W, Andreeff M, Ruvolo P . The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia. 2005; 19(8):1350-4. DOI: 10.1038/sj.leu.2403828. View

Deng W, Kawashima H, Wu G, Jayachandran G, Xu K, Minna J . Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer.... Cancer Res. 2007; 67(2):709-17. DOI: 10.1158/0008-5472.CAN-06-3463. View

Taylor B, Reiman T, Pittman J, Keats J, de Bruijn D, Mant M . SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. J Immunother. 2005; 28(6):564-75. DOI: 10.1097/01.cji.0000175685.36239.e5. View

10.

Hong D, Kurzrock R, Supko J, He X, Naing A, Wheler J . A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012; 18(12):3396-406. PMC: 4494099. DOI: 10.1158/1078-0432.CCR-11-2703. View

11.

Nagaraj S, Youn J, Weber H, Iclozan C, Lu L, Cotter M . Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res. 2010; 16(6):1812-23. PMC: 2840181. DOI: 10.1158/1078-0432.CCR-09-3272. View

12.

Dressman H, Berchuck A, Chan G, Zhai J, Bild A, Sayer R . An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2007; 25(5):517-25. DOI: 10.1200/JCO.2006.06.3743. View

13.

La Porta C . Drug resistance in melanoma: new perspectives. Curr Med Chem. 2007; 14(4):387-91. DOI: 10.2174/092986707779941078. View

14.

Deeb D, Gao X, Jiang H, Dulchavsky S, Gautam S . Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR. Prostate. 2009; 69(8):851-60. PMC: 3865612. DOI: 10.1002/pros.20937. View

15.

Zhang , Chung , OLDENBURG . A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 2000; 4(2):67-73. DOI: 10.1177/108705719900400206. View

16.

Han J, Lee G, Yoo S, Yoon S, Cho E, Kim H . Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy. Pharmacogenomics J. 2009; 10(2):86-93. DOI: 10.1038/tpj.2009.46. View

17.

Collins C, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K . A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A. 2006; 103(10):3775-80. PMC: 1383649. DOI: 10.1073/pnas.0600040103. View

18.

Berns K, Hijmans E, Mullenders J, Brummelkamp T, Velds A, Heimerikx M . A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature. 2004; 428(6981):431-7. DOI: 10.1038/nature02371. View

19.

Gao X, Deeb D, Jiang H, Liu Y, Dulchavsky S, Gautam S . Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-kappaB and Notch1 signaling. J Neurooncol. 2007; 84(2):147-57. DOI: 10.1007/s11060-007-9364-9. View

20.

Ekmekcioglu S, Ellerhorst J, Prieto V, Johnson M, Broemeling L, Grimm E . Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer. 2006; 119(4):861-6. DOI: 10.1002/ijc.21767. View